Enzastaurin
- Generic Name
- Enzastaurin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H29N5O2
- CAS Number
- 170364-57-5
- Unique Ingredient Identifier
- UC96G28EQF
- Background
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
- Indication
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 218
- Registration Number
- NCT00308750
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
Enzastaurin Versus Lomustine in Glioblastoma
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 397
- Registration Number
- NCT00295815
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00267020
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Dallas, Texas, United States
A Study of LY317615 in Patients With Brain Tumors
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00190723
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bethesda, Maryland, United States
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00088205
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rotterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.